Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

COVID-19 Map Tracker | COVID-19 News Features


Globe NewsWire News Distribution Service



BENSALEM, Pa., April 08, 2021 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of FibroGen Inc. (“Fibrogen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company and its officers’ possible violations of federal securities laws.


On April 6, 2021, after the market closed, FibroGen issued a statement “provid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (‘CKD’).” Specifically, the Company stated that the safety analyses “included post-hoc changes to the stratification factors.” FibroGen further revealed that, based on analyses using the pre-specified stratification factors, the Company “cannot conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa.”

On this news, the Company’s share price fell $14.90, or 43%, to close at $19.74 per share on April 7, 2021, thereby injuring investors.

If you purchased FibroGen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to This email address is being protected from spambots. You need JavaScript enabled to view it., or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.howardsmithlaw.com


Posted: 2021-04-08 19:00:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



Related News Stories From The Web And More

Related Bing News Search Results

Press Release: INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of FibroGen Inc. (FGEN) on Behalf of Investors - Newscast

The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors

Thu, 08 Apr 2021 14:03:00 GMTThe Law Offices of Frank R. Cruz continues its investigation on behalf of FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company and its officers’ possible ...

The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf ...

Thu, 08 Apr 2021 14:02:00 GMTThe Law Offices of Frank R. Cruz continues its investigation on behalf of FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company and its officers’ possible ...

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of FibroGen Inc. (FGEN) on Behalf of Investors

Thu, 08 Apr 2021 12:03:00 GMTLaw Offices of Howard G. Smith continues its investigation on behalf of FibroGen Inc. (“Fibrogen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company and its officers’ possible ...

Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of ...

Thu, 08 Apr 2021 11:07:00 GMTGlancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of FibroGen Inc. (“Fibrogen” or the “Company”) (NASDAQ: FGEN) investors concerning the ...

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,0

Thu, 08 Apr 2021 06:13:00 GMTThe Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or “the Company”) (NASDAQ: FGEN) for ...

Related News Story Videos From Youtube